Logo image of PRTC

PURETECH HEALTH PLC - ADR (PRTC) Stock Fundamental Analysis

NASDAQ:PRTC - Nasdaq - US7462371060 - ADR - Currency: USD

18.47  +0.12 (+0.65%)

After market: 19.4 +0.93 (+5.04%)

Fundamental Rating

2

PRTC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. PRTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PRTC has reported negative net income.
In the past year PRTC has reported a negative cash flow from operations.
In multiple years PRTC reported negative net income over the last 5 years.
In the past 5 years PRTC always reported negative operating cash flow.
PRTC Yearly Net Income VS EBIT VS OCF VS FCFPRTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

1.2 Ratios

PRTC's Return On Assets of -14.22% is amongst the best of the industry. PRTC outperforms 84.49% of its industry peers.
The Return On Equity of PRTC (-26.11%) is better than 81.11% of its industry peers.
Industry RankSector Rank
ROA -14.22%
ROE -26.11%
ROIC N/A
ROA(3y)-7.68%
ROA(5y)4.46%
ROE(3y)-11.22%
ROE(5y)6.06%
ROIC(3y)N/A
ROIC(5y)N/A
PRTC Yearly ROA, ROE, ROICPRTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTC Yearly Profit, Operating, Gross MarginsPRTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K 4K -4K

More info and screens

5

2. Health

2.1 Basic Checks

PRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRTC has less shares outstanding
Compared to 5 years ago, PRTC has less shares outstanding
PRTC has a better debt/assets ratio than last year.
PRTC Yearly Shares OutstandingPRTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
PRTC Yearly Total Debt VS Total AssetsPRTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.16, we must say that PRTC is in the distress zone and has some risk of bankruptcy.
PRTC's Altman-Z score of 1.16 is fine compared to the rest of the industry. PRTC outperforms 67.56% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that PRTC is not too dependend on debt financing.
PRTC has a worse Debt to Equity ratio (0.05) than 63.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.16
ROIC/WACCN/A
WACC9.37%
PRTC Yearly LT Debt VS Equity VS FCFPRTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

PRTC has a Current Ratio of 3.68. This indicates that PRTC is financially healthy and has no problem in meeting its short term obligations.
PRTC has a Current ratio (3.68) which is comparable to the rest of the industry.
A Quick Ratio of 3.68 indicates that PRTC has no problem at all paying its short term obligations.
PRTC has a Quick ratio of 3.68. This is comparable to the rest of the industry: PRTC outperforms 44.21% of its industry peers.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.68
PRTC Yearly Current Assets VS Current LiabilitesPRTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PRTC have decreased strongly by -80.86% in the last year.
Looking at the last year, PRTC shows a very negative growth in Revenue. The Revenue has decreased by -96.01% in the last year.
Measured over the past years, PRTC shows a very negative growth in Revenue. The Revenue has been decreasing by -30.64% on average per year.
EPS 1Y (TTM)-80.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.96%
Revenue 1Y (TTM)-96.01%
Revenue growth 3Y-34.35%
Revenue growth 5Y-30.64%
Sales Q2Q%-90.86%

3.2 Future

PRTC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.61%
EPS Next 2Y16.89%
EPS Next 3Y8.74%
EPS Next 5Y3.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRTC Yearly Revenue VS EstimatesPRTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
PRTC Yearly EPS VS EstimatesPRTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTC Price Earnings VS Forward Price EarningsPRTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTC Per share dataPRTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.89%
EPS Next 3Y8.74%

More info and screens

0

5. Dividend

5.1 Amount

PRTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PURETECH HEALTH PLC - ADR

NASDAQ:PRTC (2/21/2025, 8:00:01 PM)

After market: 19.4 +0.93 (+5.04%)

18.47

+0.12 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2024-08-28/bmo
Earnings (Next)04-23 2025-04-23/amc
Inst Owners77.72%
Inst Owner Change-100%
Ins Owners5.95%
Ins Owner ChangeN/A
Market Cap442.21M
Analysts86.67
Price Target64 (246.51%)
Short Float %0.11%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.69%
PT rev (3m)-13.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)22.22%
EPS NY rev (3m)22.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 944.89
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-3.39
EYN/A
EPS(NY)-6.26
Fwd EYN/A
FCF(TTM)-5.05
FCFYN/A
OCF(TTM)-5.05
OCFYN/A
SpS0.02
BVpS13.19
TBVpS13.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.22%
ROE -26.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.68%
ROA(5y)4.46%
ROE(3y)-11.22%
ROE(5y)6.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.75%
Cap/Sales 37.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z 1.16
F-Score2
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)35.69%
Cap/Depr(5y)75.32%
Cap/Sales(3y)17.95%
Cap/Sales(5y)45.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.96%
EPS Next Y51.61%
EPS Next 2Y16.89%
EPS Next 3Y8.74%
EPS Next 5Y3.6%
Revenue 1Y (TTM)-96.01%
Revenue growth 3Y-34.35%
Revenue growth 5Y-30.64%
Sales Q2Q%-90.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.05%
EBIT Next 3Y12.38%
EBIT Next 5Y8.66%
FCF growth 1Y34.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.95%
OCF growth 3YN/A
OCF growth 5YN/A